Search

Displaying results 5551 - 5560 of 10000 in total
  1. Drug

    Mycophenolic acid

    go.drugbank.com/drugs/DB01024
    ApprovedInvestigational

    Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a calcineurin inhibitor (ciclosporin or tacrolimus) and prednisolone. … Mycophenolic acid is a potent immunosuppressant agent that inhibits _de novo_ purine biosynthesis.

    Categories: UGT1A1 Substrates with a Narrow Therapeutic Index, UGT1A6 Substrates with a Narrow Therapeutic IndexProducts: CELLCEPT ROCHE POLVO PARA INFUSION I.V. 500 MG, MYCOPHENOLAT 1A 250MG HART
  2. Drug

    Tarloxotinib

    go.drugbank.com/drugs/DB14944
    Investigational

    Tarloxotinib is under investigation in clinical trial NCT03743350 (NSCLC Exon 20 or HER2-activating Mutations).

  3. Drug

    Tioxolone

    go.drugbank.com/drugs/DB13343
    Experimental

    Categories: Anti-Acne Preparations for Topical Use
  4. Drug

    Eprozinol

    go.drugbank.com/drugs/DB13395
    Experimental

    Categories: Drugs for Obstructive Airway Diseases
  5. Drug

    GX-19 Vaccine

    go.drugbank.com/drugs/DB15891
    Investigational

    The GX-19 vaccine is a DNA vaccine created by Genexine, Inc. Company in Gyeonggi, Korea[A219758]. … As of June 2020, the vaccine candidate is undergoing Phase I and Phase IIa trials to determine dose levels for safety and efficacy[A219758,L16488].

  6. Drug

    RP-A501

    go.drugbank.com/drugs/DB17647
    Investigational

    It is being investigated for Danon disease.[L45934] … RP-A501 is a gene therapy product consisting of a recombinant adeno-associated virus serotype 9 (rAAV9) capsid containing the human LAMP2B transgene (AAV9:LAMP2B), which encodes lysosome-associated membrane

  7. Drug

    EGT-301

    go.drugbank.com/drugs/DB17649
    Experimental

    EGT-301 is a gene therapy being investigated for Hunter Syndrome.

  8. Drug

    DTX-101

    go.drugbank.com/drugs/DB17699
    Investigational

    It was previously investigated for the treatment of hemophilia B; however, the clinical development of DTX-101 was discontinued.[L46103]

  9. Drug

    Coagulin-B

    go.drugbank.com/drugs/DB17703
    Experimental

    [A259038, A259043] It was previously investigated for the treatment of hemophilia; however, the manufacturing company discontinued the Phase I trial in 2004, halting its further development and investigation

  10. Drug

    Lubazodone

    go.drugbank.com/drugs/DB09196
    Experimental

    Lubazodone (YM-992, YM-35,995) is an arylpiperazine antidepressant which was being developed as a treatment for depression and obsessive compulsive disorder, and reached phase II clinical trials, but was … It acts as a serotonin reuptake inhibitor and 5-HT2A receptor antagonist.